Edenwell Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 06-07-2024
- Paid Up Capital ₹ 0.15 M
as on 06-07-2024
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 177.22%
(FY 2022)
- Profit 238.89%
(FY 2022)
- Ebitda 385.48%
(FY 2022)
- Net Worth 107.62%
(FY 2022)
- Total Assets 43.85%
(FY 2022)
About Edenwell Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Parvez Kosgi, Kamlesh Londhe, and Shoeb Kosgi serve as directors at the Company.
- CIN/LLPIN
U85320MH2017PTC296318
- Company No.
296318
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jun 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Edenwell Therapeutics Private Limited offer?
Edenwell Therapeutics Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Services, Computer, IT & Software Training, Computer Language Training Services, ISO & Quality Management Consultants, Certification Services, Data Entry & Data Processing Service, Data Management, Company Law & Labour Law Consultants, Statutory Compliance Services.
Who are the key members and board of directors at Edenwell Therapeutics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parvez Kosgi  | Director | 19-Jun-2017 | Current |
| Kamlesh Londhe | Director | 19-Jun-2017 | Current |
| Shoeb Kosgi | Director | 21-Nov-2018 | Current |
Financial Performance of Edenwell Therapeutics.
Edenwell Therapeutics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 177.22% increase. The company also saw a substantial improvement in profitability, with a 238.89% increase in profit. The company's net worth Soared by an impressive increase of 107.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Edenwell Therapeutics?
In 2020, Edenwell Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Edenwell Therapeutics?
Unlock and access historical data on people associated with Edenwell Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Edenwell Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Edenwell Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
